Table 4 Impact of serum GGT level on PD risk by the presence of metabolic syndrome.

From: Serum gamma-glutamyltransferase activity and Parkinson’s disease risk in men and women

Metabolic syndrome

GTP

Male

p for interaction

Female

p for interaction

PD (n)

aIR

bMODEL I

cMODEL II

PD (n)

IR

MODEL I

MODEL II

No

Q1-Q3

1,571,317

48.3

1

1

0.654

1,744,781

34.4

1

1

0.457

Q4

381,167

30.1

0.67

(0.62,0.73)

0.73

(0.67,0.79)

374,765

39.2

1.06

(0.99,1.14)

1.10

(1.02,1.18)

Yes

Q1-Q3

583,526

81.1

1.44

(1.37,1.50)

1.34

(1.28,1.41)

695,514

94.1

1.76

(1.69,1.84)

1.69

(1.61,1.77)

Q4

339,277

42.5

0.95

(0.89,1.02)

1.00

(0.93,1.08)

408,058

92.0

1.82

(1.73,1.91)

1.79

(1.70,1.89)

  1. aPD incidence per 1,000 person-years, badjusted for age, cadjusted for age, BMI, income, smoking, alcohol drinking, and exercise; income categorized as the lower quartile of income and the others; smoking and alcohol drinking as yes or no; doing exercise defined as at least 20 minutes ≥1 time/week.
  2. PD, Parkinson disease; GGT, gamma-glutamyltransferase; IR, incidence rate; HR, hazard ratio; CI, confidence interval; Q1, quartile 1; Q2, quartile 2; Q3, quartile 3; Q4, quartile 4.
Back to article page